ライフサイエンスコーパス: viral clearance

1 te of recurrent infection and participate in viral clearance.

2 f proinflammatory cytokines after successful viral clearance.

3 he identification of potential correlates of viral clearance.

4 lation and cytokine production) and enhanced viral clearance.

5 ar compartments and, as such, can facilitate viral clearance.

6 virus-specific T cells in order to expedite viral clearance.

7 LPR(-/-) mice enhanced morbidity and delayed viral clearance.

8 ic CD8(+) and CD4(+) T cells and inefficient viral clearance.

9 a antibodies that are critical for efficient viral clearance.

10 ce nor T-cell responses prior to spontaneous viral clearance.

11 pDC-dependent antibody production influences viral clearance.

12 specific T-cell responses, including in vivo viral clearance.

13 dinated immune response that is critical for viral clearance.

14 o be the most efficient antibody isotype for viral clearance.

15 (+) T and NK cells, which is associated with viral clearance.

16 ize liver damage by cytotoxic T cells during viral clearance.

17 delicate balance between immunopathology and viral clearance.

18 nues to drive a CD4(+) T cell response after viral clearance.

19 enous IFN-I rescues CD8(+)T cells, promoting viral clearance.

20 independent of other factors that may favour viral clearance.

21 of such complications but could also prolong viral clearance.

22 viral COPD exacerbation, which do not affect viral clearance.

23 e or during persistent infection can promote viral clearance.

24 cs for negating host immune surveillance and viral clearance.

25 tis B virus (HBV) infection is essential for viral clearance.

26 nate viral antigen-bearing cells and slowing viral clearance.

27 eningitis virus (LCMV) but have no impact on viral clearance.

28 needed in our model to explain the eventual viral clearance.

29 ith rejection before (9.1%) or after (26.0%) viral clearance.

30 cell (Teff) responses that are essential for viral clearance.

31 hepatitis B (AHB), which usually results in viral clearance.

32 he involvement of the innate immune cells in viral clearance.

33 ing that class Ia molecules are required for viral clearance.

34 us graft loss due to BKVN preferably post-BK viral clearance.

35 8 enhances their immune effector function of viral clearance.

36 other persistent antagonists with the aim of viral clearance.

37 adaptive immune response and accompanied by viral clearance.

38 ed amplification assays were used to confirm viral clearance.

39 enance of RBV uptake may contribute to rapid viral clearance.

40 fic CD8 T cell immune response necessary for viral clearance.

41 tly decline in a manner suggestive of active viral clearance.

42 ns that indicate the possibility of eventual viral clearance.

43 survival, it was necessary for STAg-mediated viral clearance.

44 ing apoptosis, and this results in decreased viral clearance.

45 henotype and suggesting their involvement in viral clearance.

46 ectly inhibit antiviral immunity and prevent viral clearance.

47 l deficiency did not significantly influence viral clearance.

48 in early infection and later contributing to viral clearance.

49 infection but increased in the airways after viral clearance.

50 to 3 weeks after infection due to failure of viral clearance.

51 induction by immunization can contribute to viral clearance.

52 might activate T-cell responses that mediate viral clearance.

53 target for long-term suppressive therapy or viral clearance.

54 virus-specific CD8 T cell response and rapid viral clearance.

55 munodominant CD8(+) T cell epitopes enhanced viral clearance.

56 aborted during chronic infection, preventing viral clearance.

57 hase and is prominent during immune-mediated viral clearance.

58 restricting virus replication and promoting viral clearance.

59 d peak viral replication but did not prevent viral clearance.

60 ong host immune response against HCV favours viral clearance.

61 ns in airway epithelium without jeopardizing viral clearance.

62 l from baseline compared to patients without viral clearance.

63 tent with this, IL-17RA was not required for viral clearance.

64 lls before migrating to the lungs to mediate viral clearance.

65 potentiate both tumor immunosurveillance and viral clearance.

66 d early infection but were not essential for viral clearance.

67 ntributing to neuroinflammation and lowering viral clearance.

68 eks followed by a delayed seroconversion and viral clearance.

69 etween antibody levels and the efficiency of viral clearance.

70 Typically, inflammasome activation leads to viral clearance.

71 -DP to HBV-RT is not associated with delayed viral clearance.

72 or pegylated interferon-alpha can result in viral clearance.

73 ped along with the inflammatory response and viral clearance.

74 es to protection from immunopathology during viral clearance.

75 athy, while downregulation of MHC-I prevents viral clearance.

76 of soluble inflammatory mediators even after viral clearance.

77 evels of inflammatory cytokines, and delayed viral clearance.

78 e responses are weak and thus rarely lead to viral clearance.

79 nhanced viremia and inflammation and delayed viral clearance.

80 s (HCV) infection long after therapy-induced viral clearance.

81 lls in the airways was associated with early viral clearance.

82 dependent factors associated with POAE after viral clearance.

83 nduction of autoimmunity as well as impaired viral clearance.

84 caused substantial RSV disease despite their viral clearance.

85 and mild hepatitis was observed, followed by viral clearance.

86 i-viral immune responses, leading to delayed viral clearance.

87 directly cleave viral DNA, thereby promoting viral clearance.

88 at adaptive T cell immunity is important for viral clearance.

89 owed a strong antiviral response and induced viral clearance.

90 ng ART concentrations in such sites enhances viral clearance.

91 DeltaF508 mice demonstrated impaired viral clearance, a slower type I interferon response and

92 h their synergistic but spatially segregated viral clearance activities.

93 l immune responses and substantially delayed viral clearance after exposure to systemic LCMV or mucos

94 th hepatitis C virus (HCV) achieve sustained viral clearance after pegylated interferon (peginterfero

95 an important determinant of lymphoid tissue viral clearance and absence of lymph node immunopatholog

96 and effector functions, which may facilitate viral clearance and alleviate liver injury.

97 to enteroviral infection, leading to reduced viral clearance and an increased risk of cardiac patholo

98 Viral clearance and associated immunopathology were meas

99 ects of the antibody are not limited to free viral clearance and blocking new infection but also incl

100 h previous studies have demonstrated delayed viral clearance and blunted effector T cell responses in

101 erformed in the index patient at the time of viral clearance and compared with an OLT cohort with per

102 severe plasma leakage occurs at the time of viral clearance and defervescence in dengue hemorrhagic

103 ation, seen in wild type (WT) B6 mice, after viral clearance and demyelination.

104 persistence of T-cell activation well beyond viral clearance and detect EBOV-specific T cells.

105 viral immune response, which is critical for viral clearance and disease resolution.

106 WAS KO mice showed reduced viral clearance and enhanced immunopathology during LCMV

107 ion, and IKKepsilon expression and inhibited viral clearance and expression of genes required for ant

108 The precise role of these molecules in viral clearance and immune-mediated liver injury is not

109 expression on nonhematopoietic cells limited viral clearance and immunopathology in infected tissues.

110 iral LRI, but the role of TCD8 impairment in viral clearance and immunopathology is unclear.

111 , CD8 T cells play an important role in both viral clearance and immunopathology.

112 ated with a delay both in the early phase of viral clearance and in illness in Treg-cell-depleted mic

113 In the current study, viral clearance and inflammation resolution were indeed

114 demonstrative differences in their rates of viral clearance and kinetics of early viral decline.

115 ution of inflammation, with implications for viral clearance and lung pathology.

116 ties of IFN-lambda4 that can be important in viral clearance and other clinical conditions.

117 innate and adaptive responses have a role in viral clearance and protection, they can also contribute

118 stinal pathogen, plays a significant role in viral clearance and protects against reinfection.

119 AECs and CD103+ DCs is crucial for effective viral clearance and recovery from injury, which has pote

120 Viral clearance and SP-D/SP-A upregulation were unimpair

121 to be associated with HCV treatment-induced viral clearance and subsequently to be a key determinant

122 indings support a critical role of T-bet for viral clearance and suggest T-bet deficiency as an impor

123 a A virus since IL-10(-/-) mice had improved viral clearance and survival after infection compared to

124 piratory viral challenge, mediating enhanced viral clearance and survival to lethal influenza infecti

125 We propose that a combination of impaired viral clearance and T-cell/macrophage dysregulation caus

126 virulence of WNVKOU was associated with poor viral clearance and the induction of a poor neutralizing

127 These data demonstrate efficient viral clearance, and a protective effect of subdominant

128 CD8(+) T cells are important for viral clearance, and although often ineffective in neona

129 ducing increased migration to MLNs, enhanced viral clearance, and attenuated lung injury.

130 impaired antiviral CD8(+) T cell responses, viral clearance, and CD8(+) T cell-mediated host recover

131 This pathway might mediate viral clearance, and disruptions might be involved in th

132 rtance in shaping adaptive immune responses, viral clearance, and immune-based inflammation, tissue-s

133 ate that interleukin-10 (IL-10) can suppress viral clearance, and interventional blockade of IL-10 ac

134 T cells are necessary for viral clearance, and many age-dependent intrinsic T cell

135 Topical prednisolone acetate interfered with viral clearance, and ocular disease rebounded in prednis

136 hroughout the viral replication cycle, rapid viral clearance, and prevention of potentially harmful i

137 l respiratory tract infection, mechanisms of viral clearance, and the well-recognized consequences of

138 onic hepatitis E but become detectable after viral clearance; and (3) that HEV-specific T-cell respon

139 ly 15%); and (iii) no visible papillomas and viral clearance ( approximately 65%).

140 CD8 T cells in the lung are as effective for viral clearance as neutralizing antibodies when present

141 ng inflammation was more prevalent following viral clearance, as leukocyte numbers peaked at 14 days

142 We found that depletion of CD8 T cells after viral clearance, as well as blockade of NKG2D, reversed

143 Regardless of the viral clearance at the end of treatment, there was a sig

144 ayed resolution of herpetic lesions, reduced viral clearance at the site of infection and draining po

145 nished RSV-induced illness without affecting viral clearance at the site of infection.

146 is increase was not the result of failure in viral clearance because viral titers in granzyme B-defic

147 LR2-mediated immune response plays a role in viral clearance because wild-type mice cleared Candid 1

148 on that recapitulates the key differences in viral clearance between early life and adulthood and fin

149 Despite viral clearance, bronchiolitis and alveolitis persisted

150 al cell shedding, which not only accelerates viral clearance but also contributes to acute obstructio

151 h CD4 and CD8 T cells not only contribute to viral clearance but also facilitate RSV-induced disease.

152 elucidate immune mechanisms that facilitate viral clearance but may also contribute to persistent lu

153 c nonresponders (NR), and those with initial viral clearance but subsequent breakthrough or relapse (

154 immunity that, on the one hand, can promote viral clearance, but alternately can increase necroinfla

155 ssion of vasculitis has been associated with viral clearance, but few studies have reported the effec

156 T cells rapidly undergo contraction upon viral clearance, but how T cell function and fate are de

157 T cells assist in viral clearance, but immune regulation serves to limit t

158 iciency enhanced T cell responses to promote viral clearance, but increased IL-22 in vivo decreased T

159 IL-33, required for viral clearance by cytotoxic T cells, is generally expre

160 Viral clearance by day 5 and clinical responses were com

161 Rapid viral clearance by pegIFNalpha was confirmed in HEV gt1,

162 sults suggest that MPA preinfection inhibits viral clearance by suppressing the antiviral response pa

163 on immunosuppressive mechanisms that prevent viral clearance by the host.

164 tively inhibited HCV replication and induced viral clearance by the IFN-alpha+RBV combination treatme

165 K(d)M2(82-90) response resulted in effective viral clearance by the subdominant epitope with less ill

166 nitored daily viral load kinetics, estimated viral clearance, calculated the half-life of the virus i

167 We propose that noncytopathic CNS viral clearance can be achieved by therapeutic antiviral

168 We showed that viral clearance can be achieved for high anti-HBV antibo

169 We further showed that viral clearance can be achieved for low equilibrium anti

170 Host defenses, while effecting viral clearance, contribute substantially to inflammatio

171 trol mice), neurological disease followed by viral clearance (Deltavhs infection of Stat1(-/-) mice a

172 sease severity but had no effect on eventual viral clearance, disease symptoms, or survival.

173 ells in regulating CD8+ T cell responses and viral clearance during chronic viral infection.

174 on alpha/beta (IFN-alpha/beta) is crucial to viral clearance during dengue virus (DENV) infection; ho

175 fine the mechanism(s) likely responsible for viral clearance during hepatitis B virus (HBV) infection

176 regulation of antiviral immune responses and viral clearance during IAV infection.IMPORTANCE The NOD-

177 F receptor blockade did not adversely affect viral clearance during influenza infection in mice.

178 pe I IFN (IFN-alpha) response is crucial for viral clearance during primary viral infections.

179 and immunopathology while preserving optimal viral clearance during respiratory virus infections.

180 The relationships between RSV load, viral clearance dynamics, and disease severity have not

181 MPV-infected mice indicated that MDA5 alters viral clearance, enhances disease severity and pulmonary

182 CD8(+) T cells, were critical for mediating viral clearance, even in the presence of a functional in

183 f 4 with reinfection, demonstrated sustained viral clearance for a median of 26 months since last HCV

184 tically examines an emerging tool to measure viral clearance from biomanufacturing streams, monitor a

185 However, viral clearance from infected MHC I(-/-) parenchyma was

186 hanges were similar over the dose range, and viral clearance from the brains occurred uniformly by da

187 illnesses of unknown origin for years after viral clearance from the circulation.

188 CD8+ cytotoxic T cells are critical for viral clearance from the lungs upon influenza virus infe

189 idity and mortality despite similar rates of viral clearance from the lungs.

190 RSV in sOP children may slow the kinetics of viral clearance from the nasopharynx and allow for viral

191 not interfere with antiviral Ab responses or viral clearance from the spleen, pancreatic lymph nodes,

192 13% of patients with viral clearance had increased LDL and 33% experienced in

193 n the Treated Hepatitis C Group who achieved viral clearance had increased LDL and cholesterol from b

194 nd that patients responding to IFNalpha with viral clearance had significantly higher serum levels of

195 Although ROS is necessary for optimal viral clearance, if not neutralized efficiently, it may

196 R343V NCRD decreased morbidity and increased viral clearance in a murine model of IAV infection using

197 eutralizing antibodies peaked at the time of viral clearance in all spontaneous resolvers, whereas ch

198 ated animals following challenge and delayed viral clearance in C3-deficient mice.

199 ron-gamma production, did not lead to faster viral clearance in CD40 transgenic mice.

200 ransfer of wild-type CD8(+) T cells restored viral clearance in Cxcr3(-/-) animals.

201 h H1N1, H3N2, and H5N1 strains, and improved viral clearance in ferrets.

202 functional avidity have been associated with viral clearance in hepatitis C virus (HCV) infection and

203 e antigen B27 is associated with spontaneous viral clearance in hepatitis C virus (HCV) infection.

204 Enhanced viral clearance in IL-10(-/-) mice was not correlated wi

205 ously known, which presumably contributes to viral clearance in infected animals.

206 The increased inflammation and reduced viral clearance in IPS-1-knockout mice was accompanied b

207 acrophages deficient in Atf3 showed enhanced viral clearance in lymphocytic choriomeningitis virus an

208 Neither mutation negatively affected viral clearance in mice, and compensation by the unmutat

209 t loss of IL-21 signaling results in reduced viral clearance in models of lymphocytic choriomeningiti

210 ute to progressive liver damage and impaired viral clearance in NASH.

211 immune response is associated with impaired viral clearance in Nlrc5(-/-) mice.

212 een associated with interferon (IFN)-induced viral clearance in patients with chronic hepatitis C.

213 This was supported by evidence of viral clearance in some animals and new infections in pr

214 ection, and this was associated with delayed viral clearance in the few surviving TRAIL(-/-) mice.

215 ge with LCMV-clone 13, resulting in impaired viral clearance in the liver.

216 ence of WNVKOU also was associated with poor viral clearance in the periphery (sera and spleen), a sk

217 med, and Sel K(-/-) mice exhibited decreased viral clearance in the periphery and increased viral tit

218 inuum outcomes were self-reported except for viral clearance in treatment-experienced participants.

219 ly impacting autoimmune susceptibilities and viral clearance in vivo.

220 ower liver disease progression and increased viral clearance in women, the disease burden from HCV in

221 timicrobial responses, which led to impaired viral clearance, increased viral dissemination, and more

222 no skin T(RM) cells showed greatly impaired viral clearance, indicating that T(RM) cells provide sup

223 Viral clearance involves immune cell cytolysis of infect

224 ls show markedly decreased contraction after viral clearance, leading to the establishment of massive

225 equire efficient T cell responses to promote viral clearance, limit immunopathology, and enhance surv

226 basal autophagy, where the former acts as a viral clearance mechanism abrogating infection, while th

227 ences of IFN activation, while important for viral clearance, modify the host proinflammatory respons

228 fluenza infection, Egr2 CKO mice had delayed viral clearance, more weight loss, and more severe patho

229 ast 3 weeks postinfection, past the point of viral clearance observed in the kidneys.

230 Spontaneous viral clearance occurred in 29 of 37 (78.4%) patients an

231 ce of pneumonitis was seen in the lungs when viral clearance occurred.

232 iral RNAs, indicating that cytokine-mediated viral clearance occurs in an antigen-independent manner.

233 Although viral clearance occurs in approximately 25% of patients

234 Successful immunity to HBV is age dependent: viral clearance occurs in most adults, whereas neonates

235 e response to HBV antigens is age dependent: viral clearance occurs in most adults, while neonates an

236 ent inflammation in the absence of effective viral clearance occurs in VZV vasculopathy and VZV infec

237 ces heterosubtypic immunity that accelerates viral clearance of a second strain, even if the external

238 as the role of NKs in mediating IFN-induced viral clearance of chronic HCV infection.

239 Robust viral clearance of HCV was observed in infected patients

240 T cells have been shown to be essential for viral clearance of mouse norovirus (MNV) infection.

241 orbidity and mortality without impairment in viral clearance or functional heterotypic immunity.

242 hough the contribution of individual NKRs to viral clearance or persistence remains to be clarified.

243 iral genome variations play a role in either viral clearance or persistence.

244 T cells play a crucial role in viral clearance or persistence; however, the precise mec

245 decreased antigenic stimulation after either viral clearance or viral variation.

246 a new mechanism by which nanoART can enhance viral clearance over native drug formulations.

247 Viral loads were low in many cases and viral clearance rapid.

248 c effector mechanisms, resulting in enhanced viral clearance, recovery from sublethal infection, and

249 Viral clearance, reinfection, and intercalating infectio

250 sion of Ag-specific naive CD8(+) T cells and viral clearance remained fully intact.

251 ction, yet their contribution to spontaneous viral clearance remains controversial.

252 Viral clearance requires effector T-cell egress from the

253 function, resulting in significant tumor and viral clearance, respectively.

254 Viral clearance results in PD-1(lo) functional virus-spe

255 LA-B 57 was associated with a higher rate of viral clearance (risk ratio = 2.0; 95% confidence interv

256 rent efforts to develop latency reversal and viral clearance strategies to eradicate established HIV

257 beginning to enter combination testing with viral clearance strategies.

258 revealed that migration is not required for viral clearance, suggesting a cytokine-mediated antivira

259 e activated during recovery, coincident with viral clearance, suggesting an important role of this ce

260 omen had a significantly higher incidence of viral clearance than did men (age-adjusted hazard ratio,

261 ion has greater influence on the kinetics of viral clearance than the efficiency of virus neutralizat

262 allenged with RSV was associated with potent viral clearance that was mediated at least partly throug

263 in IFNARKO mice than B6 mice, although after viral clearance, the frequencies of TSKB20-specific CD8+

264 meningitis virus (LCMV)-infected mice during viral clearance, the persistence of wild-type virus, or

265 es, with slopes reflecting the rate of serum viral clearance, the rate of loss of intracellular viral

266 However, after viral clearance, there was a subsequent approximately 50

267 ul to predict progression versus spontaneous viral clearance, thereby helping guide the need for anti

268 While T cells are indispensable for viral clearance, they also contribute to immunopathology

269 al to shaping the outcome of infection, from viral clearance to persistence.

270 lism by DGKs can serve a crucial function in viral clearance upon lymphocytic choriomeningitis virus

271 short time (HTST) treatment, a commonly used viral clearance upstream strategy.

272 tokines released by T cells also can promote viral clearance via noncytolytic processes.

273 or role in both tumor immunosurveillance and viral clearance via their effector functions.

274 CMI, the incidence of subsequent spontaneous viral clearance was 24 of 26 (92.3%) compared with 5 of

275 the two groups that received a loading dose--viral clearance was accelerated (P</=0.05), and the AUC

276 liver biopsies from SVR patients showed that viral clearance was accompanied by decreased expression

277 On-treatment viral clearance was accompanied by rapid downregulation

278 Interestingly, faster viral clearance was associated with a >/=4-fold NAb resp

279 ntaneous, but not antiviral therapy-induced, viral clearance was associated with increased antiviral

280 RSV compared with nonallergic mice, whereas viral clearance was comparable in both mouse groups.

281 Moreover, viral clearance was impaired in UNC93B1 mutant mice, des

282 atients with primary infections, spontaneous viral clearance was observed in 83% of reinfected patien

283 No further compromise of viral clearance was observed when DCs were continuously

284 Similarly, viral clearance was rescued upon restored IPS-1 signalin

285 ce during hepatitis B virus (HBV) infection, viral clearance was studied in a panel of immunodeficien

286 Because viral clearance was unimpaired, the study highlights the

287 le for Ag presentation persistence following viral clearance was unknown until now.

288 ce normally resistant to TMEV infection with viral clearance, we have previously demonstrated that RO

289 Antiviral CD8(+) T cell responses and viral clearance were impaired in miR-155-deficient mice,

290 during viral infection to promote efficient viral clearance while limiting immunopathology.

291 ptimal immunosuppressive regimens, to enable viral clearance while preventing rejection and donor-spe

292 ffectors at the site of infection to promote viral clearance, while decreasing the numbers of bystand

293 tes of tumor recurrence and occurrence after viral clearance with DAA agents.

294 ted with attenuated weight loss and enhanced viral clearance with primary challenge in STAT4-/- mice

295 4] vs 217 [44.6], p<0.001); it also impaired viral clearance, with increased lung tissue viral RNA co

296 e receptors continued to increase even after viral clearance, with most virus-specific lung TCD8 expr

297 luticasone and rhinovirus alone and improved viral clearance without having any effect on suppression

298 ction resulting in three different outcomes: viral clearance without neurological disease (Deltavhs i

299 cific T cell response, resulting in impaired viral clearance, without affecting CD4 T cell responses.

300 es to influenza challenge result in improved viral clearance yet do not prevent the morbidity associa

301 virally infected CNS is vital for promoting viral clearance yet may contribute to neuropathology if